P
The startup develops cell-based therapies by utilizing proprietary cell-engineering technology to modify platelet concentrates into RNA-based therapeutic delivery vehicles. This approach enhances the efficacy of treatments while minimizing toxicity, addressing the need for safer and more effective biopharmaceutical solutions.
Updated 3 months ago
Funding
$560K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops cell-based therapies by utilizing proprietary cell-engineering technology to modify platelet concentrates into RNA-based therapeutic delivery vehicles. This approach enhances the efficacy of treatments while minimizing toxicity, addressing the need for safer and more effective biopharmaceutical solutions.